Screener / SEC EDGAR /CIK 0001521036 /10-K filed Feb 26, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Diagnostics

Lantheus Holdings, Inc. LNTH

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 26, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

29.8% to 20.2% (-9.6 pts)

The MD&A has no sentence that names a cause for this change.

Gross margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

64.4% to 61.1% (-3.3 pts)

“The decrease in gross profit in 2025, as compared to 2024, is primarily due to the decrease in PYLARIFY net sales price.”

Read it in the 10-K

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-28.4%

The MD&A has no sentence that names a cause for this change.

Net income

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-25.2%

“Other income, net decreased by $5.9 million for the year ended December 31, 2025 as compared to the prior year period, primarily due to a decrease in interest income of approximately $13.4 million due to lower average cash balances after the acquisitions of Evergreen in April 2025 and Life Molecular in July 2025.”

Read it in the 10-K

“The decrease in the effective tax rate in 2025 is primarily due to the change in the valuation allowance related to the fluctuation in value of our investment in equity securities.”

Read it in the 10-K

Revenue

Change, FY to Dec 31, 2025 vs Dec 31, 2024

+0.5%

The MD&A has no sentence that names a cause for this change.

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

1 of 2 years explained
  • FY 2025 +0.5%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +18.3%

    “The increase in revenues for the year ended December 31, 2024, as compared to 2023, is primarily due to increased PYLARIFY and DEFINITY sales volume, as well as revenue generated from sales for investigational use of NAV-4694 and MK-6240.”

    Read it in the FY 2024 10-K

    “The increase is offset, in part, by a decrease in net sales royalties in 2024 primarily due to the sale of the rights to our RELISTOR royalty revenue asset in 2023.”

    Read it in the FY 2024 10-K

Gross margin

2 of 2 years explained
  • FY 2025 -3.3 pts

    “The decrease in gross profit in 2025, as compared to 2024, is primarily due to the decrease in PYLARIFY net sales price.”

    Read it in the FY 2025 10-K
  • FY 2024 +9.7 pts

    “The increase in gross profit for the year ended December 31, 2024, as compared to the prior year period, is primarily due to an increase in PYLARIFY and DEFINITY sales volume in 2024 and the impairment of the AZEDRA intangible asset recorded in 2023.”

    Read it in the FY 2024 10-K

Operating margin

0 of 2 years explained
  • FY 2025 -9.6 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +1.7 pts

    The FY 2024 MD&A has no sentence that names a cause for this change.

Net income

2 of 2 years explained
  • FY 2025 -25.2%

    “Other income, net decreased by $5.9 million for the year ended December 31, 2025 as compared to the prior year period, primarily due to a decrease in interest income of approximately $13.4 million due to lower average cash balances after the acquisitions of Evergreen in April 2025 and Life Molecular in July 2025.”

    Read it in the FY 2025 10-K

    “The decrease in the effective tax rate in 2025 is primarily due to the change in the valuation allowance related to the fluctuation in value of our investment in equity securities.”

    Read it in the FY 2025 10-K
  • FY 2024 -4.4%

    “Other income, net decreased by $29.1 million for the year ended December 31, 2024 as compared to the prior year period primarily due to the gain on sale of the RELISTOR licensed intangible asset associated with net sales royalties of $51.8 million recorded in 2023, for which there is no comparable amount in 2024.”

    Read it in the FY 2024 10-K

    “The increase in the effective tax rate in 2024 is primarily due to the valuation allowance established on the current year unrealized loss on our investment in equity securities, and a benefit recorded in 2023 related to our RELISTOR royalty asset, which resulted in additional net operating losses becoming available for utilization under Internal Revenue Code Section 382.”

    Read it in the FY 2024 10-K

Cash from operations

0 of 2 years explained
  • FY 2025 -28.4%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +78.5%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LNTH/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.